12:00 AM
 | 
Mar 30, 2009
 |  BioCentury  |  Finance

2Q09 milestones

2Q09 milestones

Company Product Indication Milestone Milestone date
Advanced Life (NASDAQ:ADLS) Cethromycin Community-acquired pneumonia (CAP) FDA panel 6/2/09
AGI Therapeutics (ISE:A9I; LSE:AGI) Rezular arverapamil (AGI-003) Diarrhea-predominant irritable bowel syndrome (IBS-D) Prelim Ph III data 2Q09
Allergan (NYSE:AGN) Botox botulinum toxin Prevent headaches in patients with chronic migraine Final Ph III data; submit sBLA Mid-2009
Amylin (NASDAQ:AMLN)/ Alkermes (NASDAQ:ALKS)/ Eli Lilly (NYSE:LLY) Exenatide once weekly Type II diabetes Ph III data; submit NDA 2Q09
Arca (NASDAQ:ABIO) Gencaro bucindolol Chronic heart failure PDUFA date 5/31/09
Arpida (SIX:ARPN) IV iclaprim Complicated skin and skin structure infection (cSSSI) EMEA action Mid-2009
AstraZeneca (LSE:AZN; NYSE:AZN)/ Bristol-Myers (NYSE:BMY)/ Otsuka Onglyza saxagliptin...

Read the full 886 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >